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Abstract
Background: The X-linked Inhibitor of Apoptosis (XIAP) has attracted much attention as a cancer drug target. It is
the only member of the IAP family that can directly inhibit caspase activity in vitro, and it can regulate apoptosis
and other biological processes through its C-terminal E3 ubiquitin ligase RING domain. However, there is
controversy regarding XIAP’s role in regulating tumor cell proliferation and survival under normal growth
conditions in vitro.
Methods: We utilized siRNA to systematically knock down XIAP in ten human tumor cell lines and then monitored
both XIAP protein levels and cell viability over time. To examine the role of XIAP in the intrinsic versus extrinsic cell
death pathways, we compared the viability of XIAP depleted cells treated either with a variety of mechanistically
distinct, intrinsic pathway inducing agents, or the canonical inducer of the extrinsic pathway, TNF-related
apoptosis-inducing ligand (TRAIL).
Results: XIAP knockdown had no effect on the viability of six cell lines, whereas the effect in the other four was
modest and transient. XIAP knockdown only sensitized tumor cells to TRAIL and not the mitochondrial pathway
inducing agents.
Conclusions: These data indicate that XIAP has a more central role in regulating death receptor mediated
apoptosis than it does the intrinsic pathway mediated cell death.
Background
An underlying feature of all human cancer is uncon-
trolled cell proliferation. However, for a tumor to
increase in cell mass and malignant potential, the
increase in replication rate must be accompanied by
suppression of apoptosis [1]. While tumor cells can sub-
vert many apoptotic regulators, the anti-apoptotic IAP
family is thought to have a central role in this process.
There are eight IAPs in humans. All IAPs contain
multiple functional domains that potentially modulate
many biological processes, including apoptosis. For
instance, IAPs have a role in cell-cycle regulation
through mitotic spindle formation, ubiquitination of tar-
get proteins, and modulation of several signal transduc-
tion pathways [2]. Elevated IAP protein levels are
common in many tumor types, and a wealth of data
supports their role in suppressing cell death, although
the exact mechanisms by which different IAPs mediate
this effect remains unclear [3,4]
XIAP is the most thoroughly characterized of this
family, and is the only member that can directly inhibit
the proteolytic activity of caspases in vitro (reviewed in
Eckelmen [5]). Caspase inhibition is mediated through
an 80 amino acid motif, the Baculovirus IAP Repeat
domain (BIR), common to all IAPs. By contrast, cIAPs
can also directly interact with caspases, but largely to
target caspase degradation through the ubiquitin ligase
activity of the C-terminal RING domain [6]. Impor-
tantly, XIAP inhibits caspases at both the initiation
phase (caspase-9) and the execution phase (caspases-3
and 7) of apoptosis [7]. In light of these activities, XIAP
inhibition through small molecules or antisense has
received considerable pharmaceutical industry focus,
and multiple agents have progressed to clinical trials [3].
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Viable cells of many well-studied cancer cell lines have
been reported to exhibit high steady-state levels of acti-
vated caspases in the absence of other markers of cell
death [8]. The resistance of these cells to apoptosis is
thought to be mediated, at least in part, by XIAP. If
XIAP function is essential for survival of these cancer
cells, then its inhibition by pharmacological or genetic
targeting should increase the rate of apoptosis, without
the requirement of additional exogenous signals. XIAP
loss of function has been studied extensively using var-
ious genetic tools including germ line deletion [9],
somatic cell deletion [10], and both transient and stable
mRNA knockdown. The results have varied widely; in
some reports XIAP knockdown alone resulted in
decreased viability, while other studies demonstrated no
effect. Mice harboring XIAP null alleles are viable and
do not exhibit any overt defects in developmental or
homeostatic apoptosis, aside from a slight delay in
mammary alveolar development [11,12]. These same
XIAP null mice crossed to the TRAMP mouse model of
prostate cancer did not result in an alteration in tumor
progression, suggesting that XIAP is not a critical regu-
lator of tumor apoptosis in this context [13]. However,
loss of XIAP function can sensitize some cell lines in
vitro to apoptosis mediated by activation of either the
extrinsic, caspase 8 dependent pathway, using exogenous
ligands such as TRAIL [10,14] and TNFa [15], or che-
motherapeutic agents, which largely activate the intrin-
sic, caspase 9-dependent pathway [16-18]
Some of the different outcomes in XIAP depleted cells
may be attributable to varying functional dependence on
XIAP. On the other hand, there are conflicting reports
even in the same cell line. In MCF-7 cells, Hu et. al.,
[19] reported that siRNA-mediated knockdown of XIAP
had no effect on cell viability in the absence of an exo-
genous apoptotic stimulus. By contrast, Zhang et. al.
[20] reported a 70% decrease in MCF-7 viability within
60 hr after transient siRNA-mediated loss of XIAP.
Also, Lima et. al. [21] reported an approximately 50%
decrease in viability in MCF-7 cells, 96 hr post transfec-
tion with XIAP-targeted siRNA. In another example, the
effect of XIAP depletion in NCI-H460 cells ranged from
approximately 20% [14] to 55% reduced viability [22].
The reported differences in phenotype upon XIAP
k n o c k d o w nf o rag i v e nt u m o rc e l ll i n ec o u l db eaf u n c -
tion of degree and or duration of knockdown, the meth-
odology for quantifying viability, or a more subtle
parameter such as cell-culture conditions.
We present a systematic study of siRNA mediated
knockdown of XIAP in human tumor cell lines of
diverse tissue origin, including cell lines used in previous
reports. In addition to assessing the effect of XIAP
knockdown under normal growth conditions, we also
explored whether loss of XIAP sensitizes tumor cells to
either intrinsic or extrinsic inducers of cell death. Inter-
estingly, loss of XIAP function sensitizes human tumor
cell lines to TRAIL, but not inducers of the intrinsic
death pathway.
Methods
Cell Lines
DU-145, HCT-116, MCF7, PC-3 and SW-620 were from
the Division of Cancer Treatment and Diagnosis, National
Cancer Institute (Frederick, Maryland). A-375, BxPC-3, LS
174T, and T24 were from American Type Culture Collec-
tion (Manassas, VA). PATU-I cells were from Dr. David
Hockenberry at the Fred Hutchinson Cancer Research
Center (Seattle, WA). All cell lines were maintained in
RPMI 1640 medium (Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum (Invitrogen) at 37°
with humidified air containing 5% CO2.
siRNA Studies
Transfections with siRNA: Silencer® Select XIAP siRNAs
were from Perkin Elmer Applied Biosystems (Foster City,
CA). All XIAP depletions were carried out using Silencer®
Select siRNA ID# s1455, except in Figure 1 where siRNA
ID# s1456 was compared to s1455. Silencer® Negative
Control #1 siRNA (Perkin Elmer,#AM4611) was included
in each experiment. PLK1 siGENOME® SMARTpool ®
siRNA (Cat. No. M-003290-01-0005) and Non-targeting
pool (Cat. no D-001810-10-05) were from Thermo Scien-
tific (Waltham, MA). Cells were trypsinized, washed in
medium containing serum, adjusted to 5 × 10
6 cells/mL in
RPMI 1640 supplemented with 10% fetal bovine serum. 2
×1 0
6 cells in a 400 uL volume were transfected with
s i R N Ab ys i n g l ep u l s ee l e c t r o p o r a t i o ni naG e n eP u l s e r ®
C u v e t t e( B i o - R a d )w i t ha0 . 4c me l e c t r o d eg a pu s i n ga
Gene Pulser Xcell™ Electroporation system (Bio-Rad, Her-
cules, CA) set to 230 volts, 875 μF.
Western Blot
Cells were lysed in modified radioimmunoprecipitation
buffer (mRIPA; 10 mM Tris, 150 mM NaCl, 1% (v/v) NP-
40, 0.5% deoxycholate, 0.1% SDS, 5 mM EDTA, pH 7.4)
containing cOmplete protease inhibitor cocktail (Roche
Applied Science, Indianapolis, IN) 48 hr after transfection.
Total protein of the clarified lysates was quantitated by
Lowry Assay (Biorad DC protein assay). NuPAGE® LDS
Sample Buffer and Sample Reducing Agent were added to
the lysates and heated to 85°C for 10 mins. 20 μg of total
cell protein was separated in NuPAGE 4-12% Bis Tris Gel
and transferred to a nitrocellulose membrane using an
iBlot® Dry Blotting System (Invitrogen). Membranes were
incubated in Blocking Buffer (LI-COR, Lincoln, NE) for 30
m i n u t e sa tr o o mt e m p e r a t u re, followed by 60 minute
incubations with mouse monoclonal antibodies against
XIAP (BD Transduction Laboratories, Cat. No. 610716),
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Page 2 of 13Hsp90 (BD Transduction Laboratories, Cat. No. 610418),
or PLK1 (Cell Signaling Technology Cat. No. 208G4). Fol-
lowing incubation with an IRDye® Conjugated Goat Anti
Mouse IgG (LI-COR), protein bands were quantified using
an Odyssey® Infrared Imaging System. Graphing of data to
determine XIAP levels was performed using Graphpad
PRISM® software. Percent XIAP levels were calculated as
follows:
% XIAP = (fluorescence XIAP band of sample-bkgrd/
fluorescence Hsp90 band of sample-bkgrd) ÷ (fluores-
cence XIAP band of untreated cells-bkgrd/fluorescence
Hsp90 of untreated cells-bkgrd)
Viability Assays
After transfection, cells were immediately diluted in
RPMI 1640 supplemented with 10% fetal bovine serum
and added to clear bottom white wall 96 well plates at a
concentration of 2500 cells/well in a 100 μLv o l u m e .
100 μL of ATPlite™ 1 step reagent was added to each
well and the luminescence was measured using a Spec-
tramax®L microplate luminometer. Data was acquired
using SOFTMAX®Pro software. Graphing and statistical
analysis was performed using Graphpad PRISM® soft-
ware. For experiments to determine TRAIL sensitivity,
soluble human recombinant KillerTRAIL™ (Alexis Bio-
chemicals, San Diego) was added at 32 hr after transfec-
tion; cells were incubated for an additional 24 hr prior
to addition of ATPlite™.
Results
Efficient siRNA-mediated knockdown of XIAP protein
levels
XIAP protein levels were monitored in 10 human tumor
cell lines derived from different tumor types (Table 1
and Figure 1). The range of XIAP protein levels was
Figure 1 XIAP protein levels in a panel of human tumor cell lines. A. XIAP levels were monitored by Western blot from lysates of tumor
cells. B. Quantification by LICOR Odyssey imaging. XIAP levels were normalized to the loading control HSP90 (Materials and Methods).
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Page 3 of 13relatively narrow, with only a 2.5-fold difference between
the highest (e.g SW-620 and BxPC3) and lowest (e.g.
HCT-116) expressing cell lines. The relatively high
XIAP expression in SW-620 cells was consistent with
published work, where it was also shown that these cells
are resistant to TRAIL mediated apoptosis [23]. More-
over, reduction of XIAP protein levels by siRNA knock-
down sensitized SW-620 cells to TRAIL killing. Based
on these data, we chose SW-620 cells to optimize an
electroporation-based siRNA protocol for efficient
knockdown of XIAP protein. The cells were electropo-
rated with increasing concentrations of the siRNAs
s1455 and s1456 (Dharmacon Inc). Decreasing XIAP
protein levels were correlated with increasing concentra-
tions of both siRNAs (Figure 2). The dose-response for
each siRNA was similar and the maximum knockdown
was achieved at 1 μM; XIAP protein levels in s1455 and
s1456 treated cells were 11.5% and 12.5% of untreated
controls, respectively. Since there was no significant dif-
ference between the two siRNAs, we chose s1455 for all
subsequent experiments, which were all performed with
1 μM of siRNA to ensure maximum knockdown. This
concentration of siRNA is typical of studies that have
employed electroporation [18,24,25]
The kinetics of XIAP knockdown was assessed over
five days (Figure 3). A decrease in protein levels was evi-
dent at 24 hr, at 23% of untreated cells. A nadir of 10%
was observed at 48 hr. Recovery began by 72 hr, with
XIAP levels of 26%, 40%, and 50% of controls detected
at 72, 96, and 120 hr, respectively.
Effect of XIAP protein knockdown on tumor cell viability
The effect of XIAP depletion on viability of the 10
human tumor cell lines was measured at various time
points over 96 hr. These cell lines were either wild-type
or mutant at the tumor suppressor gene, p53 (Table 1).
Some reports have indicated that wild-type p53 status
correlates with sensitivity to XIAP knockdown [26,27].
Cells were electroporated with 1 μM XIAP siRNA s1455
or control siRNA. XIAP levels in cells treated with
s1455 siRNA ranged from 6% to 26% of untreated cells
at 48 hr (Figure 4A). In 6 of the 10 cell lines, there was
no significant difference in viability at any time point
between the XIAP depleted cells and control siRNA
treated cells (Figure 4B). In the remaining 4 cell lines
there was a modest, but statistically significant, 10-20%
decrease in cell viability, albeit at only one of the time
points. In MCF-7 cells there was a 20% decrease in via-
bility at 24 hr and in PC-3 cells a 12% decrease at 72 hr.
At all other time points, cell number in s1455 treated
MCF-7 and PC-3 cells was equivalent to that of control
siRNA treated cells. Similarly, in both LS-174T and T24
cells there was a 20% and 13% decrease in viability, at
48 hr, respectively, that was not observed at the other
time points. As a positive control for siRNA mediated
tumor cell death, SW620 cells were electroporated with
aP L K 1s i R N A( 1μM). As expected for this well vali-
dated cancer target [28,29] there was a 64%, 75% and
84% decrease in viability at 48, 72 and 96 hr post elec-
troporation, respectively. (75% PLK1 knockdown at 48
hr; Additional File 1). The lack of effect in the majority
of the cell lines, and the modest and transient nature of
the decreased viability in the other cell lines, suggests
that in many tumor cell lines under normal in vitro
growth conditions, XIAP has no essential role regulating
proliferation or survival.
XIAP depleted cells are sensitized to TRAIL but not
intrinsic pathway inducing agents
Several studies have reported XIAP depletion increases
sensitivity to TRAIL mediated apoptosis
[10,14,17,23,30-32]. We exposed s1455 treated cells to
TRAIL to determine if XIAP knockdown was sufficient
to sensitize them (Figure 5). In 6 of 10 cell lines, XIAP
depletion increased sensitivity to TRAIL mediated death,
indicating that the death receptor pathway is functional
in those cells and that XIAP functions as a negative reg-
ulator of caspase-8 mediated cell death. Similar results
were obtained in the SW-620 cell line with the s1456
siRNA indicating that the observed effects were not spe-
cific to siRNA s1455 (Additional File 2). Minimal or no
sensitivity to TRAIL was observed in the other 4 cell
lines, with or without XIAP knockdown. The lack of
TRAIL mediated killing in these other cell lines may
result from several possibilities, such as insufficient
death receptor expression (DR4 and DR5), the glycosyla-
ton state of these receptors or high decoy receptor
expression [33,34]. In the one resistant line (DU-145)
for which there is publicly available gene expression
data http://dtp.nci.nih.gov/mtweb/search.jsp, the DR4/
DR5 expression is similar to the other cell lines that
were also sourced from the NCI-60 panel (e.g. SW-620)
and thus would appear to be sufficient to engage TRAIL
mediated killing. To determine whether the degree to
which XIAP knockdown sensitized cells to TRAIL was
Table 1 Human tumor cell lines.
Cell Line Cancer Type P53 Status
A-375
a Melanoma functional
BxPC-3
b Pancreatic mutant
PATU-1 Pancreatic unknown
DU-145
c Prostate mutant
PC-3
c Prostate mutant
SW-620
c Colon mutant
HCT-116
c Colon functional
LS 174T
d Colon functional
MCF7
c Breast functional
T24
e Bladder mutant
a [42], b [43], c [44], d [45], e [46]
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Page 4 of 13Figure 2 Dose dependent increase in XIAP knockdown with XIAP siRNA s1455 and s1456. SW620 cells were electroporated with the
concentrations of siRNA indicated. After 48 hr, cells were lysed and XIAP levels were monitored by Western blot. A. s1455 B. s1456 C.
Quantification by LICOR Odyssey imaging. Percent XIAP levels are expressed relative to the mean of untreated cells.
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Page 5 of 13additive or synergistic in nature, we determined the via-
bility of SW620 cells with a titration of both s1455
XIAP siRNA and TRAIL alone and in combination
(Additional File 3). The Combination Index [35] indi-
cated synergy at all 3 titrations.
To explore the role of XIAP as a negative regulator of
apoptosis mediated through the intrinsic pathway, we
treated XIAP-depleted HCT-116 and SW-620 cells with
a variety of standard-of-care chemotherapeutics, the
proteasome inhibitor bortezomib and the HDAC inhibi-
tor SAHA. All of these agents are thought to engage the
mitochondrial-based, intrinsic pathway, although by dis-
tinct mechanisms [36-39]. Twenty four hours post
electroporation, cells were treated with varying concen-
trations of the therapeutic compounds. Cell viability was
determined at both 24 and 48 hours post compound
addition, thus ensuring that cells were exposed to the
agents during maximal XIAP knockdown. None of the
compounds significantly impacted cell viability in either
cell line at 24 hr (Figure 6A and 6C). By contrast, signif-
icant dose-dependent cytotoxicity was observed at 48 hr
for all agents (Figure 6B and 6D). In contrast to the
combined effect of XIAP knockdown and TRAIL, no
significant increase in cytotoxicity was observed when
t h e s ea g e n t sw e r ec o m b i n e dw i t hX I A Pk n o c k d o w n ,
compared with the various control groups (Figure 6B
Figure 3 Kinetics of siRNA mediated XIAP knockdown. SW620 cells were electroporated with 1 μM s1455 or 1 μM control siRNA. Samples
were collected every 24 hours and XIAP levels were detected by Western Blot (A) and (B) quantified by LICOR Odyssey imaging. XIAP values
were normalized to the loading control, HSP90. Percent XIAP protein levels are expressed relative to the mean of control siRNA at 24 hr. 1 μM
control siRNA (unfilled square) and 1 μM XIAP siRNA (black square).
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Page 6 of 13Figure 4 XIAP depletion in a panel of tumor cell lines.A .X I A Pl e v e l sw e r em o n i t o r e db yW e s t e r nblot from lysates of untreated cells
(unfilled square), electroporated cells, (grey square), cells electroporated with 1 μM control siRNA (dark grey square), or 1 μM s1455 XIAP siRNA
(black square) 48 hr following electroporation. XIAP levels were quantified by LICOR Odyssey imaging. Percent XIAP levels are expressed relative
to the untreated control for each cell line. B. Viablity of XIAP depleted cells was measured at 24, 48, 72 and 96 hr post electroporation; untreated
cells (unfilled square), electroporated cells (light grey square), cells electroporated with 1 μM control siRNA (dark grey square), or 1 μM s1455
XIAP siRNA (black square).
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Page 7 of 13Figure 5 Effect of XIAP depletion on tumor cell viability and TRAIL sensitivity. XIAP depleted cells were exposed to TRAIL 40 hr following
electroporation, and viability was measured 24 hr following TRAIL exposure Untreated cells (black circle); Electroporated cells (black square); 1
μM control siRNA (black triangle) 1 μM XIAP siRNA (inverted black triangle). Percent viability is expressed relative to untreated controls for each
cell line. A similar result was obtained with the s1456 siRNA in SW620 cells (Additional File 2).
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Page 8 of 13Figure 6 Effect of XIAP depletion on chemosensitivity of HCT-116 and SW620 cells. Cells were electroporated with 1 μM control siRNA
(con siRNA) or 1 μM s1455 XIAP siRNA. HCT-116 and SW-620 were treated with an array of chemotherapeutic agents for 24 hr (A and C,
respectively) or 48 hr (B and D). For the 24 hr exposure, the agents were added 32 hr following electroporation. For the 48 hr exposure, the
agents were added 24 hr following electroporation. Untreated cells (black circle); Electroporated cells (black square); 1 μM control siRNA (black
triangle) XIAP siRNA (inverted black triangle).
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Page 9 of 13and 6D; Table 2 Similar results were obtained with these
same agents in the PC-3 prostate cancer cell line (Addi-
tional File 4) Table 2 To verify efficient knockdown in
the HCT-116 and SW-620 cells, XIAP protein levels
were determined in parallel cultures of both cell lines at
48 hr post electroporation (knockdown nadir). XIAP
mRNA was efficiently targeted in these cells with XIAP
protein levels at 13% and 17% of the untreated SW-620
and HCT-116 cells, respectively (Additional File 5).
Discussion
Here we report that transient, siRNA-mediated depletion
of XIAP alone does not significantly decrease human
tumor cell viability. We interpret the results to mean that
XIAP does not have an essential role in growth and
survival of tumor cell lines under normal, optimized
growth conditions in vitro. This conclusion is consistent
with a lack of effect on developmental apoptosis in mice
harboring a germ line XIAP mutation and in transformed
mouse embryo fibroblasts derived from these XIAP
knockout mice [9]. Similar results were obtained with
human colorectal cancer cells in which the XIAP locus
was deleted via homologous recombination [10]. How-
ever, in these studies and others using transient or stable
XIAP knockdown, loss of XIAP function sensitized the
cells to TRAIL induced apoptosis. Our study is a more
expansive survey, and supports the idea that XIAP has a
critical role in negatively regulating death receptor
mediated apoptosis across a wide array of tumor cell
lines derived from diverse tissue types. Surprisingly, simi-
lar enhancement of apoptosis was not observed with
multiple mechanistically distinct chemotherapeutics or
the proteasome inhibitor bortezomib, or the HDAC inhi-
bitor SAHA. All of these agents are thought to induce
apoptosis predominantly (but perhaps not exclusively)
through the mitochondrial pathway, involving cyto-
chrome c and SMAC release and subsequent activation
of caspase-9 by the apoptosome. Our data strongly sug-
gest that XIAP has a more central role in inhibiting the
extrinsic caspase-8 mediated death pathway than the
intrinsic, caspase-9 dependent pathway. One potential
explanation for the difference between extrinsic versus
intrinsic death inducers is that the latter cause a release
of SMAC, an endogenous inhibitor of XIAP. In wild-type
cells, the caspase inhibitory activity of XIAP may be neu-
tralized by SMAC following a robust intrinsic death path-
way signal, essentially mimicking XIAP depletion.
Therefore, no further increase in apoptotic response
would be expected in XIAP siRNA treated cells. Support
of this hypothesis comes from the elegant studies of the
Prehn group, where loss of XIAP function in staurospor-
ine treated HeLa cells did not accelerate substrate clea-
vage after detection of mitochondrial outer membrane
permeabilization [40].
In contrast to our studies, Ras/E1A transformed MEFs
derived from XIAP KO mice exhibited an increased sen-
sitivity to the apoptosis inducing effects of etoposide
compared to their wild-type counterparts [9]. It is possi-
ble that Ras/E1A transformed MEFs are under different
apoptotic pressures than the human cancer cells used in
our study, resulting in XIAP having a more central role
in suppressing intrinsic pathway mediated cell death.
Testing the effects of other mechanistically distinct
inducers of the intrinsic cell death pathway in Ras/E1A
t r a n s f o r m e dM E F ss h o u l dh e l pc l a r i f yt h i sa n dd e t e r -
mine if the observed effects in MEFs are specific to
etoposide.
Yang et al [8] reported that several cell lines, including
a subset of those used in this study (BxPC-3, MCF-7,
Table 2 Sensitivity of XIAP depleted HCT-116, SW-620
and PC-3 tumor cells to various mechanistically distinct
anti-cancer agents.
Drug Cell
line
EC50 (μM)
Untreated Electroporated Control
siRNA
XIAP
siRNA
Bortezomib HCT-
116
0.0075 0.0050 0.0047 0.0045
Doxorubicin HCT-
116
0.29 0.13 0.16 0.11
Etoposide HCT-
116
34.11 12.99 10.62 8.90
Paclitaxel HCT-
116
0.0083 0.0040 0.0024 0.0031
SAHA HCT-
116
2.014 0.98 0.67 0.51
Vincristine HCT-
116
0.015 0.0067 0.0035 0.0045
Bortezomib SW-
620
0.0036 0.0025 0.0025 0.0017
Doxorubicin SW-
620
0.79 0.657 0.48 0.43
Etoposide SW-
620
31.79 25.55 33.68 22.70
Paclitaxel SW-
620
0.017 0.0067 0.0086 0.0064
SAHA SW-
620
1.69 0.98 1.29 0.97
Vincristine SW-
620
0.035 0.013 0.031 0.0095
Bortezomib PC-3 0.01 0.0063 0.0037 0.0041
Doxorubicin PC-3 0.15 0.073 0.038 0.038
Etoposide PC-3 41.96 16.58 26.13 16.76
Paclitaxel PC-3 0.0028 0.00090 0.00067 0.00037
SAHA PC-3 1.762 0.72 0.068 0.53
Vincristine PC-3 0.0025 0.0016 0.0016 0.0016
Potency (EC50) determinations from the dose response curves in Figure 5
(HCT-116 and SW-620) and Additional File 5 (PC3) were determined using
non-linear regression and a least squares fit (GraphPad Prism software)
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Page 10 of 13and SW-620) exhibited high basal levels of activated cas-
pase-3 and -8 activity in the absence of other markers of
apoptosis. It was argued that these cells were non-apop-
t o t i cv i aac o m p e n s a t o r yi n c r e a s ei nX I A Pe x p r e s s i o n ,
which neutralized the caspase activity. Within the same
study, over-expression of XIAP-associated factor 1
(XAF-1) in MCF-10A and MDA-MB-231 resulted in an
increase in apoptosis. However, the biological activities
of XAF-1 are complex and not yet fully elucidated, and
thus it is difficult to ascertain whether this increase in
cell death is solely mediated by XIAP. The more defini-
tive XIAP knockdown experiments were not performed.
If viable tumor cells such as BxPC3 and SW620 do in
fact have activated caspases, our data suggests that these
“death enzymes” are unlikely to be directly inhibited by
XIAP, but rather by some other mechanism. Alterna-
tively, in the context of XIAP knockdown the level of
active caspases is still below a threshold necessary to
induce cell death. Since 100% knockdown is never
achieved with siRNA, the residual XIAP protein in the
siRNA treated cells may be sufficient to inhibit the acti-
vated caspases present in these cells.
Several authors have reported that functional p53 is
required for XIAP depletion to result in cell death.
Tong and colleagues [26] found that the p53 positive
MKN-45 gastric carcinoma cell line exhibited an ele-
vated apoptotic rate following XIAP depletion, while the
p53 mutant cell line MKN-28 was unaffected. Mohapa-
tra and colleagues [27] reported that XIAP depletion did
not result in increased apoptosis in p53 wild type
LNCaP or p53 deficient PC-3 prostate cancer cells
although over-expression of p53 in both cell lines
resulted in apoptosis following XIAP depletion. Our stu-
dies included cell lines that harbor wild-type and mutant
(loss-of-function) p53, however, there was no obvious
correlation between response to XIAP knockdown and
p53 status.
Recently, multiple reports indicated that tumor cell
death induced by multiple, chemically distinct SMAC
mimetics was in fact dependent on the proteasomal
degradation of multiple members of the IAP family and
subsequent induction of TNFa production and caspase-
8 mediated death [41]. Treated cells that did not have
detectable levels of TNFa did not undergo apoptosis
nor did TNFa-positive cells that were simultaneously
treated with a TNFa blocking antibody. These results
lend support to our conclusions from the knockdown
experiments that under normal growth conditions in
vitro, most tumor cells have not sufficiently engaged an
apoptotic pathway such that their survival is dependent
on XIAP. Some other death signal is needed (e.g. TNFa
production or exogenous TRAIL), which, together with
XIAP antagonism results in enhanced apoptosis. One
outstanding question is whether the anti-tumor activity
of the SMAC mimetics in vivo is also dependent on
engagement of the TNFa pathway. It is possible that the
associated stresses of in vivo tumor growth (e.g.
hypoxia) generate a death signal (activated caspases)
that is sufficient to render the tumor cells sensitive to
inhibition of XIAP solely via the disruption of the cas-
pase 9/XIAP interaction. In support of this notion, mul-
tiple reports have shown that stable shRNA or antisense
knockdown of XIAP resulted in decreased tumor cell
growth, as subcutaneous xenografts in vivo,b u tn o ta s
culture mono-layers, in vitro [14,18,32]. In vivo studies
with inducible shRNAs that target XIAP in both nascent
and established tumors may help resolve this issue, and
should provide further insight for validation of XIAP as
a cancer drug target.
Conclusion
Our work is consistent with others and predicts that
agents that simply disrupt the caspase-3/9-XIAP interac-
tion may hold limited therapeutic promise as monother-
apy and that their utility will be likely found in the
combination setting, in particular with therapies that
engage the extrinsic death receptor pathway. Ultimate
validation of XIAP as a cancer drug target will come
from the clinical development of both the SMAC
mimetics and the anti-sense based XIAP cancer thera-
pies, both of which have recently entered Phase I clinical
trials.
Additional file 1: Effect of depletion of Polo-like kinase 1 (PLK1) on
cell viability. SW-620 cells were electroporated with the concentrations
of siRNA indicated. (A and B). After 48 hr, cells were lysed, and PLK1
protein levels were detected by Western blot and quantified by LICOR
Odyssey imaging. C. Cell viability was measured at 24 hr (unfilled square),
48 hr (light grey square), 72 hr (dark grey square) and 96 hr (black
square).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
11-S1.PPT]
Additional file 2: Effect of XIAP depletion on viability and TRAIL
sensitivity in SW620 cells using an alternate siRNA. A. Lysates of
SW620 and HCT-116 cells were collected 48 hr following electroporation
with 1 μM control siRNA or XIAP siRNA s1456, and XIAP levels detected
by western blot and quantified using LICOR Odyssey imaging (B).
Untreated cells (unfilled square), electroporated cells (light grey square),
cells electroporated with 1 μM control siRNA (dark grey square), or 1 μM
s1456 XIAP siRNA (black square). Percent XIAP levels are expressed
relative to the untreated control. C. Viability of XIAP depleted cells was
measured at 24, 48, 72 and 96 hr. Untreated cells (unfilled square),
electroporated cells (light grey square), cells electroporated with 1 μM
control siRNA (dark grey square), or 1 μM s1456 XIAP siRNA (black
square). D. XIAP depleted cells were exposed to TRAIL 40 hours following
electroporation, and viability was measured after 16 hr. Percent viability is
expressed relative to untreated controls. Untreated cells (black circle),
electroporated cells (black square), cells electroporated with 1 μM control
siRNA (black triangle), or 1 μM s1456 XIAP siRNA (inverted black triangle).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
11-S2.PPT]
Additional file 3: Measurement of synergism of XIAP depletion and
TRAIL on viability of SW620 cells. Cells were electroporated with
Sensintaffar et al. BMC Cancer 2010, 10:11
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Page 11 of 13varying concentrations of siRNA and TRAIL was added 40 hr post
electroporation. A and B. Viability was measured using ATPlite 16 hr
following addition of TRAIL. Combination index was determined using
Compusyn software. A combination index of < 0.1 is indicative of very
strong synergism. (Chou et. al., 2006). 1 μM s1456 XIAP siRNA (black
circle). TRAIL (black square) TRAIL and 1 μM s1456 XIAP siRNA (black
triangle). C. XIAP protein levels at 48 hr post electroporation.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
11-S3.PPT]
Additional file 4: Effect of XIAP depletion on chemosensitivity of
PC-3 cells. Cells were electroporated with 1 μM control siRNA (con
siRNA) or 1 μM s1455 XIAP siRNA. All compounds were added 24 hr
following electroporation and incubated for 72 hr. Untreated cells (black
circle); Electroporated cells (black square); 1 μM control siRNA (black
triangle) XIAP siRNA (inverted black triangle).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
11-S4.PPT]
Additional file 5: XIAP protein levels in XIAP depleted SW620 and
HCT-116 cells. Lysates of SW620 and HCT-116 cells were collected 48
hours following electroporation with 1 μM control siRNA or XIAP siRNA
s1455, and XIAP protein levels detected by Western blot (A) and
quantified using LICOR Odyssey imaging (B). Parallel cultures from the
same electroporations were used to determine XIAP depletion on
chemosensitivity (Figure 5). Percent XIAP protein levels are expressed
relative to the mean of untreated controls.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
11-S5.PPT]
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